The accumulation of phosphorylated tau protein (pTau) in the entorhinal cortex (EC) is the earliest tau pathology in Alzheimer's disease (AD). Tau tubulin kinase-1 (TTBK1) is a neuron-specific tau kinase and expressed in the EC and hippocampal regions in both human and mouse brains. Here we report that collapsin response mediator protein-2 (CRMP2), a critical mediator of growth cone collapse, is a new downstream target of TTBK1 and is accumulated in the EC region of early stage AD brains. TTBK1 transgenic mice show severe axonal degeneration in the perforant path, which is exacerbated by crossing with Tg2576 mice expressing Swedish familial AD mutant of amyloid precursor protein (APP). TTBK1 mice show accumulation of phosphorylated CRMP2 (pCRMP2), in the EC at 10 months of age, whereas age-matched APP/TTBK1 bigenic mice show pCRMP2 accumulation in both the EC and hippocampal regions. Amyloid-β peptide (Aβ) and TTBK1 suppresses the kinetics of microtubule polymerization and TTBK1 reduces the neurite length of primary cultured neurons in Rho kinase-dependent manner in vitro. Silencing of TTBK1 or expression of dominant-negative Rho kinase demonstrates that Aβ induces CRMP2 phosphorylation at threonine 514 in a TTBK1-dependent manner, and TTBK1 enhances Aβ-induced CRMP2 phosphorylation in Rho kinase-dependent manner in vitro. Furthermore, TTBK1 expression induces pCRMP2 complex formation with pTau in vitro, which is enhanced upon Aβ stimulation in vitro. Finally, pCRMP2 forms a complex with pTau in the EC tissue of TTBK1 mice in vivo, which is exacerbated in both the EC and hippocampal tissues in APP/TTBK1 mice. These results suggest that TTBK1 and Aβ synergistically induce phosphorylation of CRMP2, which may be causative for the neurite degeneration and somal accumulation of pTau in the EC neurons, indicating critical involvement of TTBK1 and pCRMP2 in the early AD pathology.
Introduction
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, characterized by the loss of synapses and neurons, leading to cognitive impairment and dementia. A growing body of evidence reveals that neurons affected in AD display "a dying-back pattern", in which neurons start degenerating at the synapse or axon terminal then gradually die back toward cell-soma.
Previous neuroimaging studies report significant axonal degeneration in the perforant path (PP) region in patients with mild cognitive impairment as determined by using magnetic resonance imaging and diffuse tensor imaging [1, 2] . The PP presents an important axonal tract that connects neurons in the entorhinal cortex (EC) to the dentate gyrus (DG) and other areas of the hippocampus [3] . This pathway is essential to many types of memory, including spatial memory [4] , which is significantly impaired in AD patients. The axons of PP arise primarily from layer II neurons in the EC where somatic accumulation of hyperphosphorylated tau protein is detected in the early stage of AD. This dying-back axonal degeneration in the PP and accumulation of phosphorylated tau protein in the EC neuron are the critical initial events in AD pathophysiology in the context of the initiation and propagation of tau pathology. However, its mechanisms still remain elusive.
We have previously shown that tau-tubulin kinase1 (TTBK1), a brain-specific tau kinase, is specifically enriched in the PP of TTBK1 transgenic mice harboring BAC containing human TTBK1 genome [5] , followed by the EC, pyramidal layer of Cornu Ammonis (CA)1-3 fields and the granular layer of dentate gyrus in the hippocampal fields [6, 7] . A recent independent study has confirmed that TTBK1 mRNA is highly expressed in the human EC, subiculum, CA filed, and DG in both AD and non-demented cases [8] . TTBK1 directly phosphorylates the tau protein in vitro, and also enhances tau phosphorylation via unique activation of cyclin-dependent kinase 5 (Cdk5) upon dissociation of G-actin from Cdk5 in vitro and in vivo [6, 7, 5] . Further, TTBK1 protein expression is significantly up-regulated in frontal neocortical region of AD brain [7] , and certain genetic variations of the TTBK1 gene are associated with late-onset AD in two cohorts of Chinese and Spanish populations [9, 10] . TTBK1 transgenic mice harboring the entire genomic sequence of human TTBK1 show accumulation of hyperphosphorylated tau in the cortex (including the EC) and hippocampal formation when crossed with P301L tau mice (JNPL3) [5] . Moreover, our recent study have shown that crossing P301L tau mice with TTBK1 transgenic mice accelerates axonal degeneration of spinal motoneurons, and silencing TTBK1 partially blocks lipopolysaccharide-stimulated microglia-induced neurite degeneration [11] .
While multiple tau kinases including GSK3β, CDK5, or casein kinase 2 and tau itself have been reported to contribute to axonal degeneration in AD especially through axonal transport deficit [12] , no kinase except TTBK1 is specifically expressed in the EC and PP where early AD pathology evolves. Thus, we hypothesize that TTBK1 may play a critical role in axonal degeneration of the PP through phosphorylation and aggregation of tau in AD.
In this study, we investigated the role of TTBK1 in AD pathology using an APP/ TTBK1 double transgenic mouse model. We specifically focused on the synergistic effect of TTBK1 and APP on phosphorylation of collapsing response mediator protein-2 (pCRMP2), an anterograde cargo transporter of tubulin dimer and a critical mediator of growth cone collapse that is also found in the neurofibrillary tangles [13] , to elucidate the mechanism of axonal degeneration of the PP and accumulation of phosphorylated tau protein and pCRMP2 in the EC and hippocampal region in AD mouse models. AD patients' brain samples were also tested to find the association between pathology measured on the Braak scale and TTBK1 and pCRMP2 expression in the EC and hippocampal region. Here we report that TTBK1 and CRMP2 may elucidate the relationship between Aβ deposition and EC-specific accumulation of phosphorylated tau protein, and neurite degeneration in early stage of AD.
Materials and methods

Transgenic animal models
All experimental procedures using animals were approved by the Institutional Animal Care and Use Committee at Boston University School of Medicine. Tg2576 (APP) mice expressing the Swedish mutation of human APP (isoform 695) were obtained from Drs. G. Carlson and K. Ashe and maintained in B6/129 background [14] . TTBK1 transgenic mice (Line 141) harboring human TTBK1 genomic fragment were maintained in B6/129 background as described previously [7, 5, 11] . Tg2576 mice were crossed with TTBK1 mice to generate APP, TTBK1, APP/TTBK1 and non-transgenic (non-Tg) littermates, and tested at 10-11 months of age.
Immunofluorescence
Age-matched APP, TTBK1, APP/TTBK1 and non-Tg littermates (10-11 months of age) were deeply anesthetized with isoflurane inhalation and transcardially perfused with 4% paraformaldehyde in PBS (Sigma-Aldrich, St. Louis, MO). Brain tissues were cryoprotected by successive 24 h immersions in 15 and 30% sucrose in PBS, mounted in OCT compound. The tissue blocks were serially cryosectioned at 10 µm-thickness on coronal planes through regions of interest including the entorhinal cortex and hippocampal formations using a microtome cryostat (Microm HM525, Thermo Fisher Scientific), and mounted on Superfrost TM Plus slides (Thermo Fisher Scientific). The tissue sections were subjected to immunofluorescence using pT514 CRMP2 rabbit polyclonal antibody (1:2000 dilution, generated by Kaibuchi laboratory), followed by Alexa Fluor 488 (Life technologies, Grand Island, NY) secondary antibody and Dapi (1:2000 dilution, Thermo Fisher Scientific). Immunostained images were captured using inverted fluorescence microscope attached to monochromatic CCD camera (TE-2000U, Nikon Instruments, Melville, NY) and fluorescence intensity were quantified with ImageJ software (NIH).
Retrograde tracing by hippocampal injection of DiI
Paraformaldehyde-fixed mouse brain tissues were dissected in a coronal plane at -3.40mm (AP) posterior to bregma. The blocks including entorhinal cortex were post-fixed for at least 
Plasmids and TTBK1 siRNA
DNA plasmids encoding HA-tagged human full length TTBK1 (HA-TTBK1) in pcDNA3.1+
vector was generated as previously described [6] . Myc-tagged human wild-type (WT) and mutant CRMP2 (S522A, T555A) [15] contained in a pCAGGS vector, and dominant negative RhoK [pEF-BOS-Myc-RB/PH (TT)] vector [16] were kindly provided by Dr Kaibuchi's lab. TTBK1  siRNA  sequences  (clone  19; 5'-GCTCTTAAGGACGAAACCAACATGAGTGG-3') were selected and subcloned into pVL-EGFP-Puro vectors. Upstream of the green fluorescence protein (GFP) coding sequences, siRNA sequences were inserted into pSuper siRNA vectors at the Hind III restriction site.
Four putative
Tissue and Cell culture
Human neuroblastoma cell line SH-SY5Y that stably expressed wild type Tau (2N4R, 1-411; kindly provided by Roger M. Nitsch) [17, 18] or human embryonic kidney 293 cell line (HEK293) cells were maintained in a 5% CO2 humid atmosphere at 37°C in Dulbecco's modified eagle medium/Ham's F12 nutrient mixture (DMEM/F12) with 10% fetal bovine serum, 10 U/ml penicillin, and 10 µg/ml streptomycin (all from Life technologies) as described [6] .
Primary cultured murine cortical neurons were prepared from E16 embryonic CD-1 mouse brains and plated on poly-D-lysine-coated coverslips in 24-well plates (Thermo Fisher Scientific Inc., Waltham, MA) as described [11] .
DNA plasmid transfection and amyloid-β treatment
HEK 293 cells (2 × 10 6 cells / 6 well plate) were transfected with 2 μ g of plasmids (CRMP2 wild type, CRMP2 S522A mutant, or CRMP2 T555A mutant) or 20 pmol of siRNA with 10μl
Lipofectamine 2000 (Thermo Fisher Scientific). Twenty-four h after the transfection, cells were incubated with 0, 3, or 10 μ M of freshly prepared human synthetic amyloid-β peptide 1-42 
Analysis of neurite length and branches
Three days after the transfection, murine cortical neuronal cells were fixed with 4% paraformaldehyde in PBS solution, and GFP signal was captured by monochromatic CCD camera. NeuronJ plug-in was used on ImageJ (NIH, Bethesda, MD) to measure the length of axons and number of dendrites emanating from the cell soma [19] .
Immunoblotting
Whole cell lysates were prepared in RIPA lysis buffer containing 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in the presence of 1 mM PMSF, 1 mM NaF and 1 mM Na 3 VO 4 after centrifugation at 20,817 × g for 30 min at 4°C. Twenty μ g protein/sample were subjected to 4-15 % SDS-PAGE (Bio-Rad laboratories, Hercules, CA) and immunoblotted for anti-phosho-Thr514 CRMP2 (pT514-CRMP2, rabbit polyclonal, 1:1000) [20] , anti-total CRMP2 mouse monoclonal (C4G mAb, 1:500, IBL. Inc, Minneapolis, MN) [21] , and anti-TTBK1 mouse monoclonal (20 μ g/ml, clone F287-1.1-1E9) [7] .
End-binding protein 3 (EB3)-GFP Live Confocal Microscopy
SH-SY5Y cells plated on 35 mm
MatTek dishes (MatTek Corp, Ashland, MA) at 2 × 10 5 cells / dish and transfected with EB3-GFP plasmid (0.5 μ g) was co-transfected with TTBK1 or pcDNA3.1 + plasmids (0.5 μ g) as described [22, 23] . The live imaging of comet movement of EB3-GFP homodimer was captured 24h later by the following setting: 100× oil objective (NA=1.45), 488 nm excitation (100-300 ms exposure/frame, single plane), 0.53 fps for 40 frames, using the Nikon TE-2000U inverted fluorescent microscope (Nikon Instruments, Melville, NY) output port and cooled charge-coupled device camera (Coolsnap HQ, Roper Scientific, Duluth, GA) as described [24, 23] .
Immunoprecipitation assay
Recombinant Myc-tagged human CRMP2 was transiently expressed in SH-SY5Y cells stably expressing P301L human tau (2N4R) [18] , and treated with 10 μ M of freshly prepared amyloid-β peptide For in vivo tau and CRMP2 binding assay, the cortical and hippocampal tissues were dissected from mouse brains and homogenized in ice-cold RIPA buffer containing protease and phosphatase inhibitor cocktails (Roche), followed by centrifugation at 20,817 × g for 30 min at 4°C. The protein concentration of the protein extract supernatant was determined using a BCA assay kit (Thermo Fisher Scientific). pCRMP2 was immunoprecipitated from 2 mg of protein extracts by anti-phosho-T514 CRMP2 rabbit polyclonal antibody (1:100 dilution) and protein A/G sepharose (Santa Cruz Biotech, Dallas, TX), and the immunoprecipitants were blotted for phosphorylated tau (AT8) and total tau (Tau46).
Human brain specimens
The entorhinal cortex and hippocampus brain tissue sample were obtained from the Boston University AD Center Brain Bank and also the Harvard Brain Tissue Resource Center. Post mortem interval was < 24 h, if it was possible, with the brain samples from Boston University Brain Bank. The criteria for AD were based on the presence of amyloid-β neuritic plaques and neurofibrillary tangles according to the NIA-Reagan criteria for intermediate and high likelihood AD and the recent NIA Alzheimer Association's guidelines [25, 26] . The NIA-Reagan criteria take into account both the Braak staging for neurofibrillary tangles [27, 28] and the overall density of neuritic plaques based on CERAD criteria [29] . The hippocampal and entorhinal cortex tissues were obtained from the Braak stage I-IV patients. The demographic information of all of the patients from Boston University AD Center Brain Bank used for this study are described in Table 1 . Brain tissues were paraffin embedded, then cut at 8 μ m by the microtome by Boston University Pathology Laboratory Service Core. The paraffin sections were mounted on Superfrost TM Plus slides (Thermo Fisher Scientific).
Immunohistochemistry (human brain sections)
Deparaffinized sections were incubated with proteinase K (20 μg/ml) in Tirs-EDTA-CaCl 2 buffer at 37 ºC in humidified chamber and room temperature for 10 min each, rinsed in tris-buffered saline (TBS) with 0.025 % Triton X-100 and permeabilized with 0.1% Triton-X 100 in TBS for 10 min. After further washing with TBS, sections were incubated with blocking buffer (10% horse serum with 1% bovine serum albumin in TBS) for 2 h at room temperature, then incubated with following primary antibodies at 4 ºC for 48 h: TTBK1 mouse monoclonal (1:20, clone 1E9 generated by Ikezu laboratory) [7] and 3F4 anti-pCRMP2 mouse monoclonal (1: 100, ILB America), which detects pT509/pS518/pS522 [21] . Endogenous peroxidase activity was inhibited with 0.3% hydrogen peroxide (Sigma-Aldrich) incubation. Sections were then incubated with secondary anti-mouse antibody (Immpress-HRP anti-mouse IgG (peroxidase polymer detection kit, Vector Laboratories, Burlingame, CA) for 30 min. The 3,3′-Diaminobenzidine (DAB; Vector Laboratories) staining was used as a chromogen, and hematoxylin was used for counterstaining. Immunostained images were captured using a Nikon Eclipse E600 microscope and a color charge-coupled device camera (Nikon Instruments, Melville, NY). The 3F4 pCRMP2 + cells were quantified using 10 sections/donor in the EC II region, and ranked as -(< average 0.5 cell/field), + (average 0.5 -1 cell/field), ++ (average 1-2 cell/field),
DAB intensity of TTBK1 in EC and CA1 regions was measured according to the previous methods [30] . Briefly, captured images were saved as 24-bit RGB TIFF format and converted to CMYK TIFF format by adobe Photoshop CS5 software. Intensity in the Y channel of individual cells was measured as DAB + immunoreactive signals by image J software.
Signal/Noise (S/N) ratio of at least 50 cells were averaged and ranked as -(≤ 1 S/N),
, and ++++ (4 < S/N). Representative transformation from original RGB images to Y channel images in CMYK format was shown in Supplementary   Figure 1 .
Results
TTBK1 and phosphorylated CRMP2 are highly expressed in the EC and hippocampal region in AD brains
In order to investigate the involvement of TTBK1 in AD pathology at the early stage, we assessed whether the expression of TTBK1 in the EC and hippocampal region is correlated with Braak stage of AD using human brain specimens (Table 1) . Immunohistochemistry using TTBK1 monoclonal antibody (clone IE9) revealed that TTBK1 is expressed highly in the cell soma and dendrites in the EC and hippocampal neurons including the DG, subiculum and CA1-3 field ( Fig. 1A ). Intensity measurements of TTBK1 immunoreactivity in the pyramidal cell soma of layer II EC neurons and CA1 showed consistent expression of TTBK1 from Braak I to IV stages ( Table 1 ). In addition, TTBK1 + neurons were partially co-localized with AT8 + specific to pS202/pS205 phosphorylated tau (pTau) in the frontal cortex in AD patients' brains ( Fig. 1B) ,
indicative of expression of TTBK1 in tau-bearing neurons in these regions.
Immunohistochemistry against 3F4 detecting phosphorylated CRMP2 (pCRMP2) at pT509/pS518/pS522 showed pCRMP2 + neurons as early as Braak I in the EC, subiculum and hippocampal CA1-3 fields and we found that the number of pCRMP2 + neurons were correlated with Braak stages (Fig. 1C and Table 1 ). In addition, we observed co-localization of pCRMP2 and pS422 pTau in the CA1 field as determined by immunostaining of the adjacent sections of human brain tissue with 3F4 (for pCRMP2) and PS422 (for pTau, Figure 1D ). Pervious study reported that colocalization of TTBK1 with PS422 in pre-tangle neurons determined by immunohistochemistry with AD and non-symptomatic control brain samples [8] , indicating a synergistic effect with TTBK1 and pCRMP2 in early tau pathology.
These data demonstrate that both TTBK1 + and pCRMP + are expressed in the EC and hippocampal neurons in AD patients' brains from the early Braak stage, and pTau + neurons show co-localization with TTBK1 or pCRMP2, suggesting the potential contribution of TTBK1 in pCRMP2 and pTau accumulation.
Synergistic enhancement of pCRMP2 accumulation by TTBK1 and APP expression in the mouse brain
To assess whether increased expression of TTBK1 and Aβ accumulation directly induces pCRMP2 accumulation in vivo, we crossed Tg2576 mice expressing KM670/671NL Swedish mutation of human APP 695 (APP mice) [14] and TTBK1 mice expressing human TTBK1 from bacterial artificial chromosome [7] to generate TTBK1, APP, APP/TTBK1, and non-Tg littermates. These mice were tested at 10-11 months of age for immunofluorescence against pT514-CRMP2 in the EC and hippocampal regions. pT514-CRMP2 was detected in the neurons of layer II/III of the EC of APP, TTBK1 and APP/TTBK1 mice but not in non-Tg mice ( Fig. 2A , green). APP/TTBK1 mice show the most pronounced accumulation of pCRMP2 in the EC region, followed by TTBK1 and APP mice (Fig. 2B) . These data support the previous in vivo demonstration of the age-dependent accumulation of pCRMP2 in the cortical region of Tg2576 [31] . Further, APP/TTBK1 mice also showed accumulation of pCRMP2 in the granular cell layer of the dentate gyrus (DG), suggesting the synergistic effect of APP and TTBK1 expression in this region ( Fig. 2C -D, green). CA field did not show any pCRMP2 accumulation with these 3 mouse models. Taken together, we observed expression of pCRMP2 in the EC in aged TTBK1
and AD mouse models, which was exacerbated in APP/TTBK1 mice, whereas pCRMP2 accumulation in the DG was only observed in APP/TTBK1 mice.
Axonal degeneration in the perforant path (PP) of TTBK1 and APP transgenic mice
We have previously reported the specific accumulation of TTBK1 immunoreactivity in the PP of TTBK1 mice and significant accumulation of phosphorylated neurofilament heavy chain in the EC layer II/III, which is indicative of axonal degeneration [7] . Accumulation of pT514-CRMP2
is also indicative of the growth cone collapse in vitro [15, 32, 20] . In order to investigate the involvement of TTBK1 and Aβ in the axonal degeneration of the PP, we tested the retrograde transport of DiI from the DG to the EC region through the PP. Retrograde tracer DiI was injected into the outer molecular layer of the DG of the hippocampal region of TTBK1, APP, APP/TTBK1 and non-tg littermates, and the accumulation of DiI in the PP and EC regions was examined. Interestingly, we observed significant reduction of DiI signals in the PP and layer II/III region of the EC in TTBK1 mice and, to the lesser extent, APP mice compared to age-matched non-tg littermates ( Fig. 3A-B ). The reduction of DiI signals was exacerbated in APP/TTBK1 mice compared to either TTBK1 or APP mice. Thus, we found that the intensity of DiI signal in the EC region was the highest in the non-tg group, followed by APP, TTBK1 and APP/TTBK1 mice ( Fig. 3C-D) . Taken together, these data demonstrate that TTBK1 and APP expression individually induces axonal degeneration of EC neurons in the PP, and that co-expression of TTBK1 and APP further enhances the axonal degeneration. Importantly, axonal degeneration in the PP are positively correlated with pCRMP2 accumulation in the EC as previously tested with those mouse models( Fig. 2 B) , suggesting the orchestrated effect by TTBK1, Aβ and CRMP2 phosphorylation leading to compromised axonal integrity.
Aβ and TTBK1 reduce microtubule polymerization kinetics
The collapsin molecules, such as semaphorin or Eph family, mediate growth cone collapse through phosphorylation of CRMP2 [15] . CRMP2 is a cargo molecule to carry α /β-tubulin hetero-dimers to the tip of microtubules via its binding to kinesin [33] . The collapsin-mediated phosphorylation of CRMP2 leads to the dissociation between itself and the tubulin dimers and kinesin, which triggers growth cone collapse and neurite retraction [34] . Given that Aβ and TTBK1 may not only induce phosphorylation of tau but also potentially CRMP2, a key molecule to maintain the neurite integrity, we assessed if Aβ and TTBK1 has effect on the dynamics of microtubule assembly, which may contribute to the neurite destabilization observed in TTBK1, APP, and APP/TTBK1 mice. We employed confocal microscopic real-time live imaging of microtubule polymerization by monitoring transiently expressed microtubule plus-end-binding (EB) 3-EGFP in SH-SY5Y human neuronal cells. EB3-GFP forms a homodimer at the plus-end tips of polymerizing microtubules, which enabled us to analyze the velocity of microtubule polymerization ( Fig.   4A -B) [24] . Treatment of EB3-GFP-expresssing SH-SY5Y cells with freshly prepared Aβ42 oligomer or co-expression of TTBK1 significantly reduced the EB3-GFP comet velocity by 28 or 13% as compared to the mock-transfected control, respectively (Fig. 4C ). These data demonstrate that Aβ42 oligomer and TTBK1 can suppress the neurite elongation via suppression of the velocity of microtubule polymerization, which may lead to impaired neurite stability.
TTBK1 expression and Aβ stimulation induces CRMP2 phosphorylation at T514 in vitro
We have previously shown that TTBK1 activates Cdk5 via dissociation of Cdk5 from G-actin and recruitment of p35/p25 to Cdk5 [7, 35] . Other evidence has shown that Cdk5 directly phosphorylates CRMP2 at Ser522, which is the priming step of the phosphorylation of CRMP2 at threonine 514 (T514) by GSK3β and this phosphorylation of CRMP2 at T514 is critical for the induction of neurite retraction [20] . We thus examined if TTBK1 expression facilitates phosphorylation of CRMP2 at T514 via Cdk5 activation in vitro. We found that transient expression of TTBK1 in human embryonic kidney 293 (HEK293) cells induced significant phosphorylation of CRMP2 at T514 (Fig. 5A, lane 1 and 2) . This was abolished by Ser 522 to Ala mutation (S522A, lane 3 and 4) at the Cdk5 phosphorylation site, and partly abolished by Thr 555
to Ala mutation (T555A, lane 5 and 6) at the Rho kinase (RhoK) phosphorylation site [36, 32, 20] .
These data suggest that TTBK1-induced T514 CRMP2 phosphorylation is dependent on both S522 phosphorylation by Cdk5 and T555 phosphorylation by RhoK.
In addition to evidence of the relationship between TTBK1 and pCRMP2, previous reports suggest that Aβ induces pCRMP2 in a RhoK-dependent manner [37] . Using human neuronal SH-SY5Y cells, we found that Aβ42 stimulation phosphorylates endogenous CRMP2 at T514 in a dose-dependent manner (Fig. 5C ). Interestingly, we found that Aβ42-induced phosphorylation of CRMP2 at T514 is dependent on TTBK1, since the siRNA-mediated silencing of endogenous TTBK1 significantly reduces the pT514-CRMP2 level by 80% as compared to controls (Fig. 5D ). Moreover, we observed synergistic enhancement of pT514-CRMP2 levels by Aβ treatment and TTBK1 expression, which was significantly reduced by the co-expression of dominant-negative RhoK (DN-RhoK) (Fig. 5E ). These data demonstrate that Aβ42-induced pT514-CRMP2 is dependent on TTBK1, and that synergistic phosphorylation of pCRMP2 by
Aβ42 and TTBK1 is dependent on RhoK (Fig. 5B ).
TTBK1 induces neurite degeneration in a Rho-dependent manner
Recent studies have shown that phosphorylation of CRMP2, an anterograde cargo transporter of tubulin dimer, is involved in the neurite degeneration pathology in multiple neurodegenerative diseases [38] [39] . Indeed, several axon guidance molecules mediate their signaling through phosphorylation of CRMP2 [40] . Thus, based on our findings, we hypothesized that TTBK1 and Aβ suppress neurite elongation by CRMP2 phosphorylation, which is dependent on Rho-mediated RhoK activation. To test this hypothesis, primary cultured mouse cortical neurons were transiently transfected with TTBK1 and green fluorescent protein (GFP). Expression of TTBK1 dramatically shortened axon length compared to controls ( Fig. 6A-B ). Since Aβ and TTBK1-induced T514 CRMP2 phosphorylation is dependent on its T555 phosphorylation by RhoK, and Rho activates RhoK to phosphorylate CRMP2 at T514 [15] , we examined if the Rho/RhoK pathway is involved in TTBK1-mediated neurite degeneration by co-transfection of dominant negative Rho (DN-Rho). The reduced axon length was restored by co-transfected DN-Rho, while single transfection of DN-Rho had no effect as compared to the GFP control group (Fig. 6B) . Similarly, TTBK1 expression reduced the number of primary branches of dendrites, which is partially restored by the co-transfection of DN-Rho (Fig. 6C) . These data indicate that TTBK1 expression suppresses neuronal neurite extension and dendritic branching partially through the Rho/RhoK pathway.
TTBK1 induces complex formation of pCRMP2 with pTau
Since TTBK1 phosphorylates CRMP2 and tau proteins, and pCRMP2 is a component of neurofibrillary tangles in the AD brain [21] , we hypothesized that TTBK1 expression or Aβ treatment directly induces physical association of CRMP2 and tau protein in their phosphorylation-dependent manner. To assess this hypothesis, Myc-tagged CRMP2 were expressed with or without TTBK1 in SH-SY5Y cells stably expressing human full-length wild type tau protein [17] , followed by treatment with freshly prepared Aβ42. The cell lysate samples were immunoprecipitated for CRMP2 by anti-Myc antibody, and immunoblotted for pTau (AT8), total tau (Tau46), and non-phosphorylated tau (Tau-1). TTBK1 expression significantly induces CRMP2 binding to tau, which was enhanced by Aβ42 treatment (Fig. 7A-B , top panels), while Aβ42 treatment itself, conversely had no effect on the binding (Fig. 7A-B, top panels) . The physical association of CRMP2 to tau appears to be dependent on tau phosphorylation, since no
Tau-1 (specific to non-phosphorylated tau) immunoreactivity was observed in CRMP2-immunoprecipitated samples (Fig. 7A, top 
pCRMP2 binds to pTau in the EC of TTBK1 and APP/TTBK1 mouse brain
To determine whether TTBK1 induces pTau and pCRMP2 complex formation in vivo, we assessed accumulation of pTau in pCRMP2-positive neurons in the specific brain regions in TTBK1 and APP mouse models. Our attempt to detect pTau in the EC or hippocampal region by AT8 or PHF-1 staining in these mice was unsuccessful at this age. This suggests that the endogenous tau expression is insufficient for detecting the pTau/CRMP2 complex formation by immunofluorescence. Therefore, brain lysates from the EC and DG with TTBK1 and APP mouse models were immunoprecipitated for T514-phosphorylated CRMP2 and immunoblotted for tau ( Fig. 8A-B ). pCRMP2 forms a complex with pTau in the EC regions of TTBK1 and APP/TTBK1 mice, while this complex formation in the hippocampal region was only detected in APP/TTBK1 mice (Fig. 8A) . The immunoreactivity of co-precipitated tau (AT8 or Tau46) was strongest in APP/TTBK1, followed by TTBK1, APP mice and non-Tg littermates in the EC (Fig.   8B ), whereas it was only significant in the hippocampus with APP/TTBK1 mice (Fig. 8B) .
Taken together, these data demonstrate that TTBK1 but not APP transgene expression alone induce the complex formation of pTau and pCRMP2 in the EC, whereas co-expression of APP and TTBK1 transgene enhance the complex formation of pTau and pCRMP2 in both the EC and hippocampal regions.
Discussion
In this study, we have demonstrated that 1) the expression of TTBK1 and accumulation of TTBK1 mice show significant axonal degeneration in the PP as determined by accumulation of phosphorylated neurofilament heavy chain in the EC region [7] . In this study, we directly assessed the axonal degeneration in the PP via DiI-tracing from the DG to EC, which was evident in TTBK1 mice and enhanced in APP/TTBK1 mice. Accumulation of pT514-CRMP2 in the EC neurons was associated with axonal degeneration observed in APP, TTBK1 and APP/ TTBK1 mouse models, therefore we hypothesized that axonal degeneration facilitated by TTBK1 are mediated by pCRMP2. CRMP2 plays a physiological role on neurite elongation by transporting α/β-tubulin heterodimer to the axonal terminal via kinesin-1-dependent anterograde transport [33, 41] . CRMP2 is also an essential molecule for regulating the axon elongation by axon guidance molecules (such as Semapholin 3A) and Aβ [40, 31] , and its collapsing function is regulated by its site-specific phosphorylation at S555, S522 and finally T514 by RhoK, Cdk5 and GSK3β, respectively [15, 32, 20] . Therefore, the lack of tubulin heterodimer supply to the plus-end of the microtuble terminal by pCRMP2 may initiate microtubule depolymerization, leading to the neurite degeneration ( Fig.9) .
Interestingly, recent studies suggest involvement of pCRMP2 in axonal degeneration pathology in multiple sclerosis both in an animal model and human brain samples [38] .
pCRMP2 + axonal staining was found in the plaque core and peripheral white matter with acute and chronic-active multiple sclerosis patients. A similar result was also found in the spinal cord injury of rat model and the experimental autoimmune encephalomyelitis mouse model. In this study, we identified a unique signaling pathway where TTBK1 induces CRMP2 phosphorylation at pT514 that is dependent on its phosphorylation at S522 and T555. Moreover, we also found that Aβ induces pT514-CRMP2 in a TTBK1 and RhoK-dependent manner. We showed that both Aβ and TTBK1 suppress microtubule polymerization as determined by EB3-GFP live imaging and the neurite degeneration in TTBK1-transfected mouse cortical neurons in a Rho-dependent manner. Taken together, these data suggest that Aβ induces Rho activation and pT514-CRMP2 leading to neurite degeneration in a TTBK1-dependent manner.
A previous study and ours showed that pCRMP2 binds to pTau [42] .
Further, phosphorylation of CRMP2 was identified in the neurofibrillary tangles isolated from AD brain [21] . We have shown for the first time that pCRMP2 is co-localized in phospho-Ser 422 positive pyramidal CA1 neurons with Braak Stage 1 human brain tissue. Recent work has shown that TTBK1 is co-localized with pS422 + pTau in neuronal cell soma containing pre-tangles but not in neuropil threads or neurofibrillary tangles [8] . Since TTBK1 can directly phosphorylate tau at S422, this data suggest its role in pS422 + pTau accumulation in pre-tangle + neurons [6, 43] .
In this study, we confirmed that TTBK1 is co-localized with AT8 + pTau in neurons, supporting the previous finding of our data showing that TTBK1/P301L tau bigenic mice exhibited enhanced AT8 + tau oligomer formation compared to P301L tau mice [5] . Moreover, p-CRMP2 and p-tau complex formation was induced by TTBK1 and exacerbated by Aβ in vitro and in vivo. Therefore, these findings suggest that together with TTBK1, pCRMP2 may be involved in the early phase of tau phosphorylation and pre-tangle formation in AD pathology.
In conclusion, our study has integrated the biological function of CRMP2, region-specific expression and molecular function of TTBK1 and Aβ accumulation as novel pathogenic mechanism of neurite degenerations and tau accumulation in the affected brain regions of AD, most importantly in the EC layer II. Since individuals in Braak stage I or II are prodromal AD and mostly cognitively normal, early intervention of neurite degeneration by TTBK1-specific inhibitors may potentially serve as a preventive therapy for AD. Unlike RhoK, GSK3β, or Cdk5, TTBK1 is specifically expressed in neurons and thus it is an attractive therapeutic target with less off-target potential. The human brain specimens are listed in Table 1 . A, Deparaffinized human brain sections (8 μm A, Stereotaxic DiI injection into stratum moleculea of dentate gyrus of a fixed and vibratome sectioned mouse brain . Transgenic littermates were sacrificed at 10 months of age and fixed brain tissues were injected with 0.5 μ l of DiI into the stratum moleculae of dentate gyrus (DG). The human brain specimens are listed in Table 1 . A, Deparaffinized human brain sections (8 μm A, Stereotaxic DiI injection into stratum moleculea of dentate gyrus of a fixed and vibratome sectioned mouse brain . Transgenic littermates were sacrificed at 10 months of age and fixed brain tissues were injected with 0.5 μ l of DiI into the stratum moleculae of dentate gyrus (DG). 
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